Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Sen T, Li J, Neuen BL, Neal B, et al. Diabetologia 2021;64:2147-2158.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Sen T, Li J, Neuen BL, Neal B, et al. Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial. Diabetologia 2021;64:2147-2158.
PMID: 34415356